Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of BL-B01D1 versus physician's choice chemotherapy in previously taxane-treated unresectable locally advanced or metastatic triple-negative breast cancer
CTR20241674Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in triple-negative breast cancer (TNBC), sponsored by Biokin Pharmaceutical. Started Jul 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20241674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241674.